EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY-NC 4.0

Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis

Samit Ghosal iD, Binayak Sinha

European Heart Journal Open · 05.03.2026 · 6 (2)

DOI: 10.1093/ehjopen/oeag071 ↗

Kurz gefasst

Kommentar in der Zeitschrift European Heart Journal Open, online erschienen am 05.05.2026. Verfasst von Samit Ghosal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Nightingale Hospital, 11 Shakespeare Sarani, Kolkata 700071, India. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Internal Medicine, Nightingale Hospital, 11 Shakespeare Sarani, Kolkata 700071, India.
  • Department of Endocrinology, Manipal Hospitals, Kolkata 700106, India.

ORCID-Profile: Samit Ghosal

Zitieren

APA

Ghosal, S., & Sinha, B. (2026). Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis. European Heart Journal Open, 6(2). https://doi.org/10.1093/ehjopen/oeag071

Vancouver

Ghosal S, Sinha B. Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis. European Heart Journal Open. 2026;6(2). doi:10.1093/ehjopen/oeag071

BibTeX
@article{Ghosal2026,
  author = {Ghosal, Samit and Sinha, Binayak},
  title = {Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis},
  journal = {European Heart Journal Open},
  year = {2026},
  volume = {6},
  number = {2},
  doi = {10.1093/ehjopen/oeag071}
}
Kostenlos starten →